BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15624359)

  • 1. [Tumor marker in primary lung cancer].
    Sugio K; Sugaya M; Hanagiri T; Yasumoto K
    J UOEH; 2004 Dec; 26(4):473-9. PubMed ID: 15624359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.
    Liu L; Teng J; Zhang L; Cong P; Yao Y; Sun G; Liu Z; Yu T; Liu M
    Biomed Res Int; 2017; 2017():2013989. PubMed ID: 28607926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
    Li Q; Sang S
    Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
    Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
    Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
    Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer.
    Kagohashi K; Satoh H; Ishikawa H; Ohtsuka M; Sekizawa K
    Med Oncol; 2008; 25(2):187-9. PubMed ID: 17968682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
    Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
    Yang-Chun F; Min F; Di Z; Yan-Chun H
    Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
    Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
    Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Significance of Tumor Marker Detection in Patients 
with Advanced Squamous Cell Carcimoma of the Lung].
    Liang P; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.